Baxter International Inc.
BAX Healthcare Medical Instruments & Supplies
Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024. In the quarter to June 2026, revenue grew 5.34%, EPS grew 33.3%, free cash flow grew 119.5% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
Follow BAX
Baxter International Inc. (BAX) EPS (diluted)
Baxter International Inc.'s EPS (diluted) for fiscal 2025 was −$1.87, compared with −$1.27 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.07. Over the past ten years it has ranged from −$4.83 (fiscal 2022) to $9.01 (fiscal 2016); the current reading is higher than 18% of that period. Baxter International Inc. ranks 39th of 49 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.87 | — |
| FY2024 | −$1.27 | — |
| FY2023 | $5.25 | — |
| FY2022 | −$4.83 | — |
| FY2021 | $2.53 | 18.78% |
| FY2020 | $2.13 | 10.36% |
| FY2019 | $1.93 | (35.02%) |
| FY2018 | $2.97 | 130.23% |
| FY2017 | $1.29 | (85.68%) |
| FY2016 | $9.01 | 411.93% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.24 | — |
| Mar 2026 | −$0.03 | — |
| Dec 2025 | −$2.19 | — |
| Sep 2025 | −$0.09 | — |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| SOLV Solventum Corporation compare | $8.18 |
| WST West Pharmaceutical Services, Inc. compare | $7.81 |
| ALGN Align Technology, Inc. compare | $5.75 |
| ATR AptarGroup, Inc. compare | $5.53 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| RGEN Repligen Corporation compare | $0.73 |
| BLCO Bausch + Lomb Corporation compare | −$0.48 |
| AVTR Avantor, Inc. compare | −$0.84 |
| BAX Baxter International Inc. | −$2.07 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BAX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement